Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Efficacy
Impetigo, paediatric
Ozenoxacin
Safety
Topical antibiotics
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
07
2019
accepted:
04
11
2019
pubmed:
21
1
2020
medline:
12
9
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5-<2, 2-<6, 6-<12, and 12-<18 years. The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days' treatment (day 6-7, end of therapy), and microbiological success rates after 3-4 days' treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years.
Sections du résumé
BACKGROUND
BACKGROUND
Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group.
METHODS
METHODS
Pooled data for patients aged 6 months to <18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5-<2, 2-<6, 6-<12, and 12-<18 years.
RESULTS
RESULTS
The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (n = 239), vehicle (n = 201), or retapamulin as internal validation control (n = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days' treatment (day 6-7, end of therapy), and microbiological success rates after 3-4 days' treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (p < 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption.
CONCLUSION
CONCLUSIONS
This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to <18 years.
Identifiants
pubmed: 31958794
pii: 000504536
doi: 10.1159/000504536
pmc: PMC7257257
doi:
Substances chimiques
Aminopyridines
0
Anti-Bacterial Agents
0
Quinolones
0
ozenoxacin
V0LH498RFO
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-207Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
Future Microbiol. 2014;9(9):1013-23
pubmed: 25340832
Scand J Infect Dis. 2014 Dec;46(12):832-7
pubmed: 25229166
Future Microbiol. 2014;9(8 Suppl):S33-40
pubmed: 25209523
Folia Microbiol (Praha). 2008;53(4):363-7
pubmed: 18759122
BMC Fam Pract. 2014 Oct 25;15:175
pubmed: 25413920
PLoS One. 2015 Aug 28;10(8):e0136789
pubmed: 26317533
JAMA Dermatol. 2018 Jul 1;154(7):806-813
pubmed: 29898217
Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92
pubmed: 24080666
Euro Surveill. 2008 Apr 03;13(14):
pubmed: 18445456
Expert Opin Pharmacother. 2005 Oct;6(13):2245-56
pubmed: 16218885
Future Microbiol. 2014;9(8 Suppl):S11-6
pubmed: 25209519
Future Microbiol. 2018 May 1;13:31-40
pubmed: 29745239
J Antimicrob Chemother. 2008 Mar;61(3):586-8
pubmed: 18222949
J Antimicrob Chemother. 2013 Aug;68(8):1714-7
pubmed: 23535880
Future Microbiol. 2018 May 1;13:3-19
pubmed: 29745242
Future Microbiol. 2014;9(8 Suppl):S23-31
pubmed: 25209521
J Clin Microbiol. 2017 Aug;55(8):2529-2537
pubmed: 28592549
J Antimicrob Chemother. 2010 Jul;65(7):1353-8
pubmed: 20430787
Acta Derm Venereol. 2010;90(1):52-7
pubmed: 20107726
Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168
pubmed: 30686133
Clin Infect Dis. 2006 Feb 1;42(3):394-400
pubmed: 16392088
J Clin Microbiol. 2007 May;45(5):1505-10
pubmed: 17344365
BMJ. 2004 Jul 10;329(7457):95-9
pubmed: 15242915
J Antimicrob Chemother. 2011 Jun;66(6):1360-4
pubmed: 21393202
Dermatol Surg. 2011 Oct;37(10):1427-33
pubmed: 21895848
Am Fam Physician. 2007 Mar 15;75(6):859-64
pubmed: 17390597
Clin Infect Dis. 2014 Jul 15;59(2):147-59
pubmed: 24947530
J Antimicrob Chemother. 2012 May;67(5):1176-80
pubmed: 22290345
J Antimicrob Chemother. 2009 Feb;63(2):420-1; author reply 421
pubmed: 18978362
Am Fam Physician. 2014 Aug 15;90(4):229-35
pubmed: 25250996